Preferences for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.

Preferences of Individuals in the United States With Personal Experience of Cancer for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.

To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients.

It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.

This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs.

To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.

Study Overview

• Status: Completed
• Conditions: Cancer
• Intervention / Treatment: Other: Discrete Choice Experiment (DCE)

• Study Type: Observational
• Enrollment (Actual): 998

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, WC2A 2AE
    • London School of Economics

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Online survey panel consisting of a US nationally representative sample (age, gender, income, race/ethnicity, US state).

Description

Inclusion Criteria:

• Individuals previously or currently diagnosed with any type of cancer.
• Individuals with immediate family members previously or currently diagnosed with any type of cancer.

Exclusion Criteria:

• Individuals without previous or current diagnosis with any type of cancer (themselves or immediate family members).

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Preferences for treatment attributes and trade-offs between attributes.	Preferences for different treatment attributes (including clinical uncertainty and wait time), and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) Questionnaire. Preferences are measured on relative utility scale (arbitrary units, no min/max). Utility indicates preference e.g., higher values are more preferred (better).	Through study completion, an average of 4-8 weeks.

Collaborators and Investigators

• Sponsor: London School of Economics and Political Science

Study record dates

Study Major Dates

• Study Start (Actual): July 7, 2023
• Primary Completion (Actual): July 20, 2023
• Study Completion (Actual): July 20, 2023

Study Registration Dates

• First Submitted: June 26, 2023
• First Submitted That Met QC Criteria: July 4, 2023
• First Posted (Actual): July 10, 2023

Study Record Updates

• Last Update Posted (Actual): June 11, 2024
• Last Update Submitted That Met QC Criteria: June 10, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Keywords: Discrete Choice Experiment
• Other Study ID Numbers: 213621

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No